Knowledge mapping of AURKA in OncologyAn advanced Bibliometric analysis (1998-2023)

Qiong Zhou1, Chunyu Tao1, Jiakai Yuan1

  • 1Department of Medical Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu Province 210093, PR China.

Heliyon
|June 24, 2024
PubMed

Insights

This bibliometric analysis explores Aurora kinase A (AURKA) research in cancer, revealing its evolution, trends, and prognostic value. Findings guide future oncology research and clinical applications for this key cancer molecule.

Area of Science:

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background:

  • Aurora kinase A (AURKA) is a critical regulator of cell division and a significant factor in cancer development.
  • Dysregulated AURKA activity promotes tumor growth, genomic instability, and resistance to cancer therapies.
  • Understanding AURKA's role is vital for advancing cancer research and treatment strategies.

Purpose of the Study:

  • To conduct a comprehensive bibliometric analysis of global research on AURKA in cancer.
  • To map the chronological development, research trends, and emerging frontiers in AURKA oncology studies.
  • To investigate AURKA signaling pathways, protein interactions, and its prognostic significance in cancer patient survival.

Main Methods:

  • Bibliometric analysis of Web of Science database (1998-2023).
  • Utilized VOSviewer, Citespace, Biblioshiny R, and Cytoscape for data mining and visualization.
  • Included a meta-analysis on the prognostic value of AURKA in cancer.

Main Results:

  • Detailed mapping of the evolution and trends in AURKA cancer research.
  • Identification of key signaling pathways and protein interaction networks involving AURKA.
  • Quantified the prognostic impact of AURKA on patient survival across various cancers.

Conclusions:

  • This study provides a comprehensive overview of AURKA research in oncology, highlighting its dynamic evolution and impact.
  • The findings offer valuable insights into AURKA's molecular mechanisms and clinical relevance.
  • This work serves as a guide for future research directions and potential therapeutic strategies targeting AURKA in cancer.

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
342
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K